Form 4: Cue Biopharma Director Receives RSU Grant

Cue Biopharma reports a restricted stock unit grant to Director Pasha Sarraf, with vesting over three years.

Summary

• Pasha Sarraf, a Director at Cue Biopharma, Inc., was granted 21,800 restricted stock units (RSUs) on July 9, 2026.
• These RSUs will vest in three equal tranches on July 9, 2027, July 9, 2028, and July 9, 2029, contingent upon Sarraf's continued service.
• Following this grant and a previous 1-for-30 reverse stock split effective April 22, 2026, Sarraf's total beneficial ownership is 32,595 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation practice for a director rather than a significant operational or financial development for the company.

Positives

• Director receives a significant RSU grant, indicating continued commitment and potential future value appreciation.
• The grant is structured with a multi-year vesting schedule, aligning the director's incentives with long-term company performance.

Risks

• Vesting of RSUs is contingent on continued service, meaning any departure before vesting dates will result in forfeiture of unvested units.
• The value of the RSUs is subject to the market performance of Cue Biopharma's common stock.

Future Outlook

The RSU grant implies management's expectation of future stock value appreciation, as the director's compensation is tied to it. Vesting schedules indicate a forward-looking incentive structure over the next three years.

Industry Context

StockSavvy.ai notes that equity grants, such as Restricted Stock Units (RSUs), are a common form of executive and director compensation in the biotechnology sector, used to attract, retain, and incentivize key personnel by aligning their financial interests with the company's long-term success and stock performance.

Stakeholder Impact

• Shareholders: The RSU grant represents potential future dilution, but also signals director commitment and alignment with shareholder interests.
• Employees: May indicate a broader compensation strategy within the company, though this filing is specific to a director.
• Management: Reinforces the use of equity-based compensation as a retention and incentive tool.

Next Steps

• Continued service by Pasha Sarraf through the respective vesting dates to receive all granted RSUs.
• Monitoring of Cue Biopharma's stock performance and corporate developments over the next three years.

Key Dates

Keywords

Form 4, SEC Filing, Cue Biopharma, Pasha Sarraf, Restricted Stock Units, RSU Grant, Director Compensation, Beneficial Ownership, Stock Vesting